

DLL3
Catalog # PVGS1819**Specification**

DLL3 - Product Information

Primary Accession [Q9NYJ7-1](#)
Species
Human

Sequence
Ala27-Arg490

Purity
> 95% as determined by Bis-Tris PAGE

Endotoxin Level
Less than 1EU per µg by the LAL method.

Biological Activity
Immobilized Anti-DLL3 Antibody, hFc Tag at 2 µg/ml (100 µl/Well) on the plate can bind DLL3[Biotin], His, Human (Cat.No.: Z03944)

Expression System
HEK293

Theoretical Molecular Weight
50.4 kDa

Formulation **Lyophilized from 0.22 µm filtered solution in PBS, 200 mM L-Arginine (pH 7.4).**

Reconstitution
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O more than 100 µg/ml.

Storage & Stability
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

DLL3 - Additional Information

Target Background
Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand. It is highly expressed on the surface of Small cell lung cancer (SCLC) and other neuroendocrine tumors. And its expression promotes SCLC migration and invasion. DLL3 agents are evaluated in several ongoing clinical studies in SCLC and other neuroendocrine tumors.

DLL3 - Protein Information

DLL3 - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

DLL3 - Images